Jason B. Muhitch, Ph.D.
Affiliations: | 2013 | Roswell Park . Cellular and Molecular Biology | State University of New York, Buffalo, Buffalo, NY, United States |
Area:
Immunology, Cell Biology, OncologyGoogle:
"Jason Muhitch"Parents
Sign in to add mentorSharon Evans | grad student | 2013 | SUNY Buffalo | |
(Overcoming Obstacles to Naive T Lymphocyte Trafficking in Anti-Tumor Immunity.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Hughson AL, Hannon G, Salama NA, et al. (2023) Local Delivery of SBRT and IL12 by mRNA Technology Overcomes Immunosuppressive Barriers to Eliminate Pancreatic Cancer. Biorxiv : the Preprint Server For Biology |
Chow J, Khan A, Gaudieri M, et al. (2023) Tumor and immune remodeling following radiotherapy in human renal cell carcinoma. Journal For Immunotherapy of Cancer. 11 |
Oliver L, Alvarez R, Diaz R, et al. (2022) Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator. Journal For Immunotherapy of Cancer. 10 |
Chow J, Hoffend NC, Abrams SI, et al. (2020) Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America |
Boland PM, Muhitch J, Abrams SI, et al. (2020) Initial correlative studies from a trial of cetuximab and pembrolizumab in metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 38: 4062-4062 |
Crombet T, Muhitch J, Mesa C, et al. (2020) Abstract CT130: Evidence for synergistic immune responses in the first-in-human (FIH) combination of B cell-activating immunotherapy (IO) with anti-PD1 immune checkpoint inhibitor nivolumab (N) as 2nd-line therapy in patients (pts) with advanced non-small cell lung cancer (aNSCLC) Tumor Biology |
Ito F, Vardam TD, Appenheimer MM, et al. (2019) thermal ablation augments antitumor efficacy of adoptive T cell therapy. International Journal of Hyperthermia : the Official Journal of European Society For Hyperthermic Oncology, North American Hyperthermia Group. 36: 22-36 |
Muhitch JB, Hoffend NC, Azabdaftari G, et al. (2019) Tumor-associated macrophage expression of interferon regulatory Factor-8 (IRF8) is a predictor of progression and patient survival in renal cell carcinoma. Journal For Immunotherapy of Cancer. 7: 155 |
Yang Y, George S, Levine EG, et al. (2019) Interim analysis of a pilot study: Impact of high-dose, single fraction radiation on immunogenicity of sipuleucel-T in metastatic castration resistant prostate cancer patients. Journal of Clinical Oncology. 37: e16538-e16538 |
Singh AK, Winslow TB, Habiby Kermany M, et al. (2017) A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |